{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"63.2","upperLimit":"87.5","value":"76.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"description":"CR rate by IRF per 2014 Lugano Classification, assessed by integrated CT and PET-based responses was defined as the percentage of participants who achieved a CR by IRF following the completion of study treatment. CR was defined as disappearance of all evidence of disease.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received brentuximab vedotin 1.8 mg/kg, IV infusion, within 1 hour of completing treatment with other IV agents, i.e., cyclophosphamide 750 mg/m\\^2 and doxorubicin 50 mg/m\\^2, on Day 1 of each 21-day cycle, and prednisone tablets, 100 mg daily, orally, on Days 1 through 5, for up to 8 cycles (6 months) or until PD, unacceptable toxicity, whichever occurred first.","id":"OG000","title":"Brentuximab Vedotin + CHP"}],"paramType":"NUMBER","populationDescription":"The FAS consisted of all enrolled participants.","reportingStatus":"POSTED","timeFrame":"Up to approximately 7 months","title":"CR Rate by IRF Per 2014 Lugano Classification","type":"SECONDARY","unitOfMeasure":"percentage of participants"}